In this study, we assessed the effect of CYP2C19 genotypes on tamoxifen metabolism and efficacy in an extensive cohort of Caucasian breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. This evidence concerns the gene CYP2C19 and breast carcinoma.